Argo Biopharmaceutical Co., Ltd. Wednesday announced a new collaboration with Swiss pharmaceutical giant Novartis. The deal focuses on developing treatments for serious heart-related conditions like high triglycerides and mixed cholesterol disorders.
This is the third partnership between the two companies and builds on their ongoing relationship.
Under the new agreement, Novartis will pay Argo $160 million upfront, with the potential for milestone and option payments worth up to $5.2 billion, plus royalties if the medicines are successfully commercialized. Novartis has also signaled interest in investing in Argo's next round of fundraising.
The collaboration gives Novartis the rights (outside of China) to two early-stage drug candidates and includes options to share development costs and profits for another drug that is expected to enter human trials in 2026. One of the key medicines in the deal, BW-00112, is already in Phase II clinical trials in the U.S. and China.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.